Biogen | BIIB - Assets


Biogen reported $29.21B in Assets for its fiscal quarter ending in September of 2025.





Assets Change Date
AbbVie USD 133.9B 3.28B Sep/2025
Acadia Pharmaceuticals USD 1.33B 105.22M Sep/2025
ALKERMES USD 2.33B 76.7M Sep/2025
Amgen USD 90.14B 2.24B Sep/2025
Bayer EUR 104.21B 1.03B Sep/2025
Biogen USD 29.21B 877.3M Sep/2025
BioMarin Pharmaceutical USD 7.61B 158.53M Sep/2025
Bristol-Myers Squibb USD 96.89B 2.21B Sep/2025
Eli Lilly USD 114.94B 14.01B Sep/2025
Gilead Sciences USD 58.53B 2.81B Sep/2025
Incyte USD 6.33B 509M Sep/2025
Merck USD 129.55B 12.02B Sep/2025
Moderna USD 12.14B 125M Sep/2025
Neurocrine Biosciences USD 4.27B 375.9M Sep/2025
Novartis USD 107.29B 2.89B Sep/2025
Pfizer USD 208.73B 2.64B Sep/2025
PTC Therapeutics USD 2.64B 9.54M Sep/2025
Regeneron Pharmaceuticals USD 40.56B 389.3M Dec/2025
Sanofi EUR 126.81B 2.99B Dec/2025
Sanofi EUR 126.81B 25.48B Dec/2025
Sarepta Therapeutics USD 3.49B 186.38M Sep/2025
Teva Pharmaceutical Industries USD 40.75B 892M Dec/2025
Ultragenyx Pharmaceutical USD 1.19B 115.82M Sep/2025
United Therapeutics USD 7.35B 556.9M Sep/2025
Vertex Pharmaceuticals USD 24.86B 825.6M Sep/2025